Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
OwnerAudrey Goddard, James Pan +1inventors
InventorsAudrey Goddard, James Pan, Minhong Yan
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Claims61
An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding a DNA98853 polypeptide comprising the sequence of amino acid residues 1 to 299 of SEQ ID NO:3, or (b) the complement of the DNA molecule of (a).
An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the cDNA in ATCC Deposit No. 203906 (DNA98853), or (b) the complement of the DNA molecule of (a).
An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding a DNA98853 polypeptide comprising the sequence of amino acid residues 1 to X of FIG. 2 (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), wherein X is any one of amino acid residues 131-141 of FIG. 2 (SEQ ID NO:3).
An isolated nucleic acid comprising DNA from the group consisting of:
- a) a DNA having at least 80% sequence identity to a DNA sequence encoding a DNA98853 polypeptide comprising amino acid residues 1 to 299 of FIG. 2 (SEQ ID NO:3);
- b) a DNA sequence that hybridizes under stringent conditions to a DNA of a);
- c) a DNA sequence that, due to the degeneracy of the genetic code, encodes a DNA98853 polypeptide of a);
- and
- d) DNA complementary to the DNA of a), b), or c).
An isolated DNA98853 polypeptide comprising amino acid residues 1 to 299 of FIG. 2 (SEQ ID NO:3).
An isolated DNA98853 polypeptide encoded by the cDNA insert of the vector deposited as ATCC Accession No. 203906 (DNA98853).
An isolated DNA98853 polypeptide comprising amino acid residues 1 to X of FIG. 2 (SEQ ID NO:3), wherein X is any one of amino acid residues 131-141 FIG. 2 (SEQ ID NO:3).
An isolated DNA98853 polypeptide comprising a polypeptide selected from the group consisting of:
- a) a DNA98853 polypeptide comprising amino acid residues 1 to X of FIG. 2 (SEQ ID NO:3), wherein X is any one of amino acid residues 131-141 of FIG. 2 (SEQ ID NO:3);
- and
- b) a fragment of a), wherein said fragment is a biologically active polypeptide.
A chimeric molecule comprising a DNA98853 polypeptide fused to a heterologous amino acid sequence.
An antibody which specifically binds to a DNA98853 polypeptide.
An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding a DNA101848 polypeptide comprising the sequence of amino acid residues 1 to 297 of FIG. 4 (SEQ ID NO:6), or (b) the complement of the DNA molecule of (a).
An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the cDNA in ATCC Deposit No. 203907 (DNA101848), or (b) the complement of the DNA molecule of (a).
An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding a DNA101848 polypeptide comprising the sequence of amino acid residues 1 to X of FIG. 4 (SEQ ID NO:6), or (b) the complement of the DNA molecule of (a), wherein X is any one of amino acid residues 131-141 of FIG. 4 (SEQ ID NO:6).
An isolated nucleic acid comprising DNA from the group consisting of:
- a) a DNA having at least 80% sequence identity to a DNA sequence encoding a DNA101848 polypeptide comprising amino acid residues 1 to 297 of FIG. 4 (SEQ ID NO:6);
- b) a DNA sequence that hybridizes under stringent conditions to a DNA of a);
- c) a DNA sequence that, due to the degeneracy of the genetic code, encodes a DNA101848 polypeptide of a);
- and
- d) DNA complementary to the DNA of a), b), or c).
An isolated DNA101848 polypeptide comprising amino acid residues 1 to 297 of FIG. 4 (SEQ ID NO:6).
An isolated DNA101848 polypeptide encoded by the cDNA insert of the vector deposited as ATCC Accession No. 203907 (DNA101848).
An isolated DNA101848 polypeptide comprising amino acid residues 1 to X of FIG. 4 (SEQ ID NO:6), wherein X is any one of amino acid residues 131-141 of FIG. 4 (SEQ ID NO:6).
An isolated DNA101848 polypeptide comprising a polypeptide selected from the group consisting of:
- a) a DNA101848 polypeptide comprising amino acid residues 1 to X of FIG. 4 (SEQ ID NO:6), wherein X is any one of amino acid residues 131-141 of FIG. 4 (SEQ ID NO:6);
- and
- b) a fragment of a), wherein said fragment is a biologically active polypeptide.
A chimeric molecule comprising a DNA101848 polypeptide fused to a heterologous amino acid sequence.
An antibody which specifically binds to a DNA101848 polypeptide.
A method of modulating apoptosis in mammalian cells, comprising exposing said cells to an effective amount of DNA98853 polypeptide or DNA101848 polypeptide.
A method of modulating NF-KB activation in mammalian cells, comprising exposing said cells to an effective amount of DNA98853 polypeptide or DNA101848 polypeptide.
A method of modulating a proinflammatory or autoimmune response in mammalian cells, comprising exposing said cells to an effective amount of DNA98853 polypeptide or DNA101848 polypeptide.
A method of inhibiting or neutralizing EDA-A2 polypeptide biological activity in mammalian cells, comprising exposing said mammalian cells to an effective amount of EDA-A2 polypeptide antagonist.
Dependencies are inferred from the claim text.